Clinical Trials Logo

Left Ventricular Hypertrophy clinical trials

View clinical trials related to Left Ventricular Hypertrophy.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05002010 Not yet recruiting - Clinical trials for Chronic Kidney Diseases

Left Ventricular Hypertrophy Among Chronic Kidney Disease Patients in Assiut University Hospital

Start date: February 2022
Phase:
Study type: Observational

Assess the prevalence and features of left ventricular hypertrophy in patients with chronic kidney disease (CKD) taking into account gender differences and stage of CKD. To detect factors those predict LVH in CKD. *to assess the right ventricle dysfunction in CKD .

NCT ID: NCT04022330 Not yet recruiting - Clinical trials for Left Ventricular Hypertrophy

Protective Monocytes and Macrophages to Limit Decompensation and Heart Damaging

PROMOMA
Start date: October 15, 2019
Phase: N/A
Study type: Interventional

The working hypothesis is that cardiac macrophages specific for the compensated cardiac hypertrophic phase limit the progression toward the decompensated state of heart failure by promoting an inflammatory environment favouring cardiomyocyte survival and preservation of the pump function. The investigators will perform studies in human plasma and monos, cardiac tissues and macrophages to validate this hypothesis.

NCT ID: NCT01382966 Not yet recruiting - Clinical trials for Chronic Kidney Disease

Serum Sclerostin Levels, Cardiovascular Parameters and Carpal Tunnel Syndrome in Maintenance Hemodialysis Patients

Start date: July 2011
Phase: N/A
Study type: Observational

Sclerostin, the product of the SOST gene, located on chromosome 17, locus q11.2 in humans, was originally believed to be a non-classical Bone morphogenetic protein (BMP) antagonist.Sclerostin was recently identified as a component of parathyroid hormone (PTH) signal transduction. Chronic kidney disease (CKD) is associated with abnormalities in bone and mineral metabolism.New advances in the pathogenesis of renal osteodystrophy (ROD) change the perspective from which many of its features and treatment are viewed. Calcium, phosphate, parathyroid hormone (PTH), and vitamin D have been shown to be important determinants of survival associated with kidney diseases. Now ROD dependent and independent of these factors is linked to survival more than just skeletal frailty.Furthermore, ROD is shown to be an underappreciated factor in the level of the serum phosphorus in CKD. The discovery and the elucidation of the mechanism of hyperphosphatemia as a cardiovascular risk in CKD change the view of ROD. Emerging current data suggests a promising role for serum measurements of sclerostin in addition to iPTH in the diagnosis of high bone turnover in chronic kidney disease-5D patients (dialysis patients). Because of the close relationship between ROD and cardiovascular disease, the aim of this study is to investigate the association between sclerostin, arteriovenous fistula thrombosis, echocardiography and carpal tunnel syndrome in maintenance hemodialysis patients.